Long-lasting shrinkage in tumor mass after discontinuation of nivolumab treatment-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Long-lasting shrinkage in tumor mass after discontinuation of nivolumab treatment

Published:2017-06 Issue: Volume:108 Page:7-8
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Kimura Hideharu,Sone Takashi,Murata Akari,Koba Hayato,Tambo Yuichi,Hara Johsuke,Abo Miki,Kasahara Kazuo

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference5 articles.

1. Detailed guideline: lung cancer (non-small cell);American Cancer Society,2015

2. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N. Engl. J. Med.,2015

3. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N. Engl. J. Med.,2015

4. Overall survival and long-term safety of nivolumab (Anti-Programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer;Gettinger;J. Clin. Oncol.,2015

5. Occurrence of psoriasiform eruption during nivolumab therapy for primary oral mucosal melanoma;Ohtsuka;JAMA Dermatol.,2015

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients;British Journal of Cancer;2024-03-26

2. Late‑onset immune checkpoint inhibitor‑related pneumonitis after cessation of sintilimab: A case report and literature review;Experimental and Therapeutic Medicine;2023-01-03

3. Late-onset programmed cell death protein-1 inhibitor-induced pneumonitis after cessation of nivolumab or pembrolizumab in patients with advanced non-small cell lung cancer: a case series;Translational Lung Cancer Research;2021-03

4. Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: Focus on Nivolumab;Southern Medical Journal;2020-11

5. Long-lasting responses after discontinuation of nivolumab treatment for reasons other than tumor progression in patients with previously treated, advanced non-small cell lung cancer;Cancer Communications;2019-11-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3